Thank you for your question, Mr. Lemire.
Indeed, we heard today from other stakeholders that Canada's entire ecosystem is in bad shape and lacking. Massive reinvestment is needed at all levels of vaccine development. It starts at the grassroots, at the basic research level. This would ensure that new technologies can always emerge and be supported in their maturation towards eventual commercialization.
We also need to solidify our technology and infrastructure capacity. In addition, we need to develop clinical trials or good manufacturing practices to ensure that our technologies that are developed in universities can mature into biotechnologies that will be commercialized.